Underscoring these vulnerabilities, it has been demonstrated that cytotoxicity generated in tumor cells with SSB repair inhibition and subsequent increase in DSB formation is exaggerated in tumors already deficient in HR (such as BRCA1/2 or RAD51 mutations) (15, 16). The gene discussed is RAD51; the disease is neoplasm.